Related Experiment Video

Updated: Mar 11, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells

Jinhua Piao1, Shiori Takai1, Takahiro Kamiya2

  • 1Department of Pediatrics and Developmental Biology, Graduate School of Medicine, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo, 113-8519, Japan.

Cancer Letters
|November 30, 2016
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors show promise for treating certain leukemias. TCF3-HLF-positive leukemia is sensitive due to suppressed DNA repair, suggesting a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly (ADP-ribose) polymerase (PARP) is crucial for DNA repair.
  • PARP inhibitors are effective in BRCA-mutated breast cancers with homologous recombination repair (HRR) defects.
  • HRR-defective hematological malignancies are potential candidates for PARP inhibitor therapy.

Purpose of the Study:

  • To investigate the efficacy of PARP inhibitors in various leukemia subtypes.
  • To identify specific leukemia genetic alterations associated with PARP inhibitor sensitivity.
  • To explore the underlying mechanisms of PARP inhibitor action in leukemia.

Main Methods:

  • Screening of leukemia-derived cell lines for PARP inhibitor sensitivity.
  • Analysis of gene expression, including TCF3-HLF and MCPH1.
  • Evaluation of homologous recombination repair (HRR) activity.
  • In vivo xenograft studies with PARP inhibitor olaparib.

Main Results:

  • Lymphoid leukemia cell lines (excluding mature B cells and KMT2A-rearranged precursors) showed sensitivity.
  • Acute myelogenous leukemia cell lines (excluding RUNX1-RUNXT1-positive) were generally resistant.
  • TCF3-HLF-positive leukemia exhibited sensitivity, linked to suppressed HRR activity and decreased MCPH1 levels.
  • Olaparib demonstrated efficacy in an in vivo xenograft model.

Conclusions:

  • PARP inhibitors represent a potential therapeutic strategy for refractory leukemias.
  • TCF3-HLF-positive leukemia is a promising subtype for PARP inhibitor treatment due to induced synthetic lethality.
  • Decreased MCPH1 levels and subsequent HRR attenuation mediate PARP inhibitor sensitivity in TCF3-HLF-positive leukemia.
Keywords:
Acute lymphoblastic leukemiaHomologous recombination repairPARP inhibitorTCF3-HLF

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.0K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.8K